Invivyd, Inc. (NASDAQ: IVVD) reported that its Chief Financial Officer, William E. Duke, sold a total of 40,627 shares of common stock over two days in mid-February 2026 for an aggregate amount of about $63,350.
The share disposals were completed in two tranches. On February 17, Duke sold 19,663 shares at a weighted average price of $1.5396. The following day, February 18, he sold 20,964 shares at a weighted average price of $1.5778. Across the two transactions, the executed prices ranged from $1.505 to $1.595.
Earlier in the week, on February 15, Duke exercised options covering 99,000 shares of common stock and converted 99,000 Restricted Stock Units into common stock. The filings indicate these actions and subsequent sales as related insider transaction activity within a short time frame.
Separately, Invivyd disclosed regulatory and program updates tied to its lead monoclonal antibody candidate, VYD2311. The company has received feedback from the U.S. Food and Drug Administration concerning the design of a planned Phase 3 study, named LIBERTY. That trial is intended to evaluate the safety and immunologic profile of VYD2311 in comparison to commercially available mRNA COVID-19 vaccines, and will also examine effects when VYD2311 is administered alongside an mRNA COVID vaccine. LIBERTY forms a central component of Invivyd's broader REVOLUTION clinical program.
Market analysts have reacted to these program developments. H.C. Wainwright has reiterated a Buy rating on Invivyd and retained a $10.00 price target, citing confidence in the company’s near-term value potential and management’s focus on delivering Phase 3 topline results, which are expected in August.
In a separate outreach effort, Invivyd announced a partnership with Olympic gold medalist Lindsey Vonn to roll out a national educational campaign about antibodies. The campaign is scheduled to begin in spring 2026 and will feature Vonn as a spokesperson. The stated aim is to increase public understanding of the role antibodies play in preventing infectious diseases.
Taken together, the insider sales, the exercise and conversion activity, regulatory feedback on a pivotal Phase 3 trial, analyst affirmation, and a public education partnership underline a period of active corporate and clinical development for Invivyd. The company is proceeding with the LIBERTY trial planning while preparing for results expected later in the year.